MARKET

SNY

SNY

Sanofi FR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.40
+1.34
+2.53%
Pre Market: 55.03 +0.63 +1.16% 07:29 05/23 EDT
OPEN
54.04
PREV CLOSE
53.06
HIGH
54.57
LOW
53.78
VOLUME
1.88K
TURNOVER
--
52 WEEK HIGH
58.10
52 WEEK LOW
45.39
MARKET CAP
136.28B
P/E (TTM)
18.55
1D
5D
1M
3M
1Y
5Y
Sanofi Receives Another Approval for Blockbuster Drug Dupixent
The go-ahead covers a chronic inflammatory disease for which the Food and Drug Administration has never before approved a treatment.
Barrons.com · 2d ago
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.
Benzinga · 2d ago
Sanofi wins FDA label expansion for Dupixent for new inflammatory condition
Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) (GCVRX) received the U.S. regulatory approval for its Dupixent injection as a treatment for eosinophilic esophagitis, a condition of allergic inflammation of the esophagus, the U.S. Food
Seekingalpha · 2d ago
Regeneron, Sanofi Report FDA Approved Dupixent As Treatment For Adults, Children Aged 12+ With Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly
Benzinga · 2d ago
BRIEF-Sanofi Says FDA Approves Dupixent As First Treatment For Adults And Children Aged 12 And Older With Eosinophilic Esophagitis
reuters.com · 2d ago
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more th...
GlobeNewswire · 2d ago
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date
PR Newswire · 2d ago
UPDATE 2-Sanofi's Dupixent wins U.S. approval for bigger use
Sanofi won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said on Friday. There are more than 160,000 patients in the United States living with eosinophil...
Reuters · 2d ago
More
No Data
Learn about the latest financial forecast of SNY. Analyze the recent business situations of Sanofi FR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SNY stock price target is 70.75 with a high estimate of 72.50 and a low estimate of 69.00.
High72.50
Average70.75
Low69.00
Current 54.40
EPS
Actual
Estimate
0.320.640.961.28
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 847
Institutional Holdings: 255.44M
% Owned: 10.20%
Shares Outstanding: 2.51B
TypeInstitutionsShares
Increased
213
10.93M
New
96
3.58M
Decreased
190
5.91M
Sold Out
42
711.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.90%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Serge Weinberg
Chief Executive Officer/Executive Board/Director
Paul Hudson
Chief Financial Officer/Executive Vice President/Executive Board
Jean Baptiste Chasseloup De Chatillon
Chief Human Resource Officer/Executive Vice President/Executive Board
Natalie Bickford
Executive Vice President/General Counsel/Executive Board
Roy Papatheodorou
Executive Vice President/Executive Board
Olivier Charmeil
Executive Vice President/Executive Board
Brendan O' Callaghan
Executive Vice President/Executive Board
John Reed
Executive Vice President/Executive Board
Arnaud Robert
Executive Vice President/Executive Board
William Sibold
Executive Vice President/Executive Board
Thomas Triomphe
Executive Vice President/Executive Board
Julie Van Ongevalle
Director
Christophe Babule
Director
Wolfgang Laux
Director
Barbara Lavernos
Director
Tran Yann
Independent Director
Rachel Duan
Independent Director
Lise Kingo
Independent Director
Patrick Kron
Independent Director
Fabienne Lecorvaisier
Independent Director
Melanie Lee
Independent Director
Gilles Schnepp
Independent Director
Diane Souza
Independent Director
Thomas Sudhof
No Data
No Data
About SNY
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Webull offers kinds of Sanofi SA (ADR) stock information, including NASDAQ:SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.